Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

NSCLC

25th Feb 2026

Plain language summary: DESTINY-Lung02 study of trastuzumab deruxtecan for HER2-mutant metastatic non-small-cell lung cancer

28th Nov 2025

Plain language summary: TROPiCS-04 study of sacituzumab govitecan in advanced urinary tract cancer

27th May 2025

Plain language summary: The IPSOS study comparing atezolizumab versus standard chemotherapy for non-small cell lung cancer patients unsuitable for platinum treatment

28th Aug 2024

DESTINY-Lung01 Study: a plain language summary on Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer

Sacituzumab govitecan (brand name: TRODELVY®) is a new treatment for certain types of advanced or metastatic breast cancer. One common type of breast cancer has at least 1 of 2 hormone receptors (HR positive) and does not have human epidermal growth factor 2 (HER2 negative). The HR and HER2 receptors are known to influence how severe a case of breast cancer is. Certain treatments will only work if a specific receptor is present on breast cancer cells. HR-positive/HER2-negative advanced or metastatic breast cancer can be treated with sacituzumab govitecan. This is a summary of the results of the TROPiCS-02 study. This study compared sacituzumab govitecan with standard chemotherapy in participants with HR-positive/HER2-negative advanced or metastatic breast cancer.
25th Jan 2024

The TROPiCS-02 study: a plain language summary on the effectiveness of sacituzumab govitecan in treating HR-positive/HER2-negative breast cancer

This plain language summary provides an overview of two of the main clinical studies that led to tepotinib’s approval, the phase I first-in-human study and the phase II VISION study
23rd May 2023

Plain Language Summary: tepotinib, a treatment for a subtype of non-small cell lung cancer called MET exon 14 skipping

This plain language summary reports the key points of a recent review article that discussed current treatment options for a type of cancer called squamous cell carcinoma (SCC) of the lung.
23rd May 2023

Plain Language Summary: treatment considerations for patients with advanced squamous cell carcinoma of the lung

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy